Early-Cancer Detection Company iCareDx Announces Corporate Name Change To Acuamark Diagnostics
iCareDx, Inc., a biotechnology company focused on blood-based early detection of cancer, today announced that it has changed its name to Acuamark Diagnostics, Inc. In conjunction with its corporate name change, the Company’s website will be available at www.acuamarkdx.com .
Globally, over 22,000 people die of cancer each day. When cancer is detected at the early stages, survival rates are generally still high. Finding cancer early with an accurate, convenient and affordable technology, and attacking it early, can vastly reduce cancer deaths, and substantially lower cancer-related healthcare expenditures.
Dr. Bernard Peperstraete, CEO of Acuamark Diagnostics, Inc. (formerly iCareDx, Inc.) stated, "Our team is excited to re-brand the Company as Acuamark Diagnostics. The name “Acuamark” incorporates several elements that play to the essence of our corporate mission, and well embodies the progress we have made towards developing an accurate diagnostic screening technology to detect low-abundance tumor markers from liquids at the earliest stages of cancer.”
Dr. Francis Barany, PhD, Professor of Microbiology and Immunology at the Weill Cornell Medicine, and lead inventor of Acuamark Diagnostics’ molecular detection technologies, adds: “In addition, the name Acuamark Diagnostics is a reflection that each cancer leaves a unique watermark in our bodies, and as with a watermark, it is barely visible, requiring one to see it in a different light.”
About Acuamark Diagnostics Inc.
Acuamark Diagnostics is a biotechnology company focused on developing screening tests technologies for blood-based early detection of cancer. Acuamark Diagnostics' technology allows for highly accurate screening of blood to detect cancer markers at the early cancer stages, before the cancer becomes untreatable. Backed by a highly experienced team, it is Acuamark Diagnostics’ mission to contribute to the global battle against cancer by detecting and attacking cancer through high-precision, early detection.
Acuamark Diagnostics, Inc.
Bernard Peperstraete, MD
Chief Executive Officer
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
SAILPOINT18.10.2018 07:03 | pressemeddelelse
SailPoint Celebrates Identity Champions at Navigate ’18 Europe
MORI-MEMORIAL-FOUNDATION18.10.2018 05:42 | pressemeddelelse
London Solidifies Lead, New York Rises Fast and Tokyo Retains 3rd in Global Rankings
NY-DILIGENT17.10.2018 21:50 | pressemeddelelse
Board Members Serve as the Critical Link to Security and Corporate Governance, Diligent Survey Finds
JPMORGAN-CHASE-BANK17.10.2018 20:15 | pressemeddelelse
JPMorgan Chase Bank Announces Initial Exchange Price for the Cash-Settled Exchangeable Bonds into Dufry Due 2021
TX-MOUSER-ELECTRONICS17.10.2018 17:42 | pressemeddelelse
Mouser Electronics and Grant Imahara Launch New Series All Things IoT about Technology Redefining How We Live
TX-MAVENIR17.10.2018 17:01 | pressemeddelelse
Telefónica Deutschland Selects Mavenir vIMS for Deployment on ‘UNICA’
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum